Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) PLAUR Antibodies:
anti-Human PLAUR Antibodies:
anti-Rat (Rattus) PLAUR Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal PLAUR Primary Antibody for BR, CyTOF - ABIN5013025
Zhang, Cai, López-Guisa, Collins, Eddy: Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. in Journal of the American Society of Nephrology : JASN 2004
Show all 8 Pubmed References
Human Polyclonal PLAUR Primary Antibody for WB - ABIN1944762
Roldan, Cubellis, Masucci, Behrendt, Lund, Danø, Appella, Blasi: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. in The EMBO journal 1990
Show all 5 Pubmed References
Human Polyclonal PLAUR Primary Antibody for IHC (p), WB - ABIN966859
Wang, Yang, Jamaluddin, Boyd: The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. in The Journal of biological chemistry 2004
Show all 2 Pubmed References
Mouse (Murine) Polyclonal PLAUR Primary Antibody for FACS, WB - ABIN4900558
van Zoelen, Florquin, de Beer, Pater, Verstege, Meijers, van der Poll: Urokinase plasminogen activator receptor-deficient mice demonstrate reduced hyperoxia-induced lung injury. in The American journal of pathology 2009
Show all 2 Pubmed References
Human Polyclonal PLAUR Primary Antibody for IP, Neut - ABIN223158
Viswanathan, Richardson, Togonu-Bickersteth, Dai, Liu, Vatsya, Sun, Yu, Munuswamy-Ramanujam, Baker, Lucas: Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. in Journal of leukocyte biology 2009
Human Monoclonal PLAUR Primary Antibody for FACS - ABIN2472715
Gadd, Majdic, Kasinrerk, Stockinger, Maurer, Eher, Knapp: M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen. in Clinical and experimental immunology 1990
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody for IHC (fro), FACS - ABIN2472714
Sillaber, Baghestanian, Hofbauer, Virgolini, Bankl, Füreder, Agis, Willheim, Leimer, Scheiner, Binder, Kiener, Bevec, Fritsch, Majdic, Kress, Gadner, Lechner, Valent: Molecular and functional characterization of the urokinase receptor on human mast cells. in The Journal of biological chemistry 1997
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody for FACS - ABIN2472717
Mondino, Blasi: uPA and uPAR in fibrinolysis, immunity and pathology. in Trends in immunology 2004
Show all 3 Pubmed References
The results establish GDE3 (show GDPD2 Antibodies) as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI (show GPI Antibodies)-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior.
The ratio of full-length versus cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease inhibitors and transforming growth factor - beta1 (TGF-beta1 (show TGFB1 Antibodies)). The role of uPAR cleavage in cell proliferation and migration was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model
Plg-RKT (show PLGRKT Antibodies) is required for plasminogen (show PLG Antibodies) binding and macrophage migration in vivo
The synergy of circulating factor suPAR and APOL1 (show APOL1 Antibodies) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.
Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.
Significance of the urokinase-type plasminogen activator (show PLAU Antibodies) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (show NPHS1 Antibodies) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an in vivo murine angiogenesis model uPAR-deficient PTEN heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN heterozygotes.
In acutely admitted patients with COPD (show ARCN1 Antibodies), elevated PLAUR levels were associated with increased risk of mortality.
This study shows that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR (show EGFR Antibodies).
High expression of U-PAR is associated with breast cancer.
To develop enzyme-resistant analogues, we applied here the Retro-Inverso (RI) approach, whereby the topology of the side chains is maintained by inverting the sequence of the peptide and the chirality of all residues. Molecular dynamics suggests that peptide RI-3 adopts the turn structure typical of uPAR-FPR1 (show FPR1 Antibodies) antagonists
results demonstrated that PLAUR induces geftinib-resistance through EGFR (show EGFR Antibodies)/p-AKT (show AKT1 Antibodies)/survivin signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients.
High Upar expression is associated with breast cancer.
Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes.
Data confirmed PLAUR and CDH11, both targets of miR (show MLXIP Antibodies)-335, to be overexpressed in gastric cancer tissues.
the present study demonstrated that EGF (show EGF Antibodies) induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression
The results establish GDE3 (show GDPD2 Antibodies) as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI (show GNPDA1 Antibodies)-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior.
Data show that urokinase-type plasminogen activator (uPA (show PLAU Antibodies)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (show PLAU Antibodies) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (show PLAU Antibodies)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA (show PLAU Antibodies) activity and RNA expression of u-PA (show PLAU Antibodies) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (show IGF2R Antibodies) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (show IGF2R Antibodies) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3